文献速递胸部肿瘤

在诊断时或诊断前后戒烟可改善肺癌患者的总生存期:系统综述与荟萃分析

Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Thorac Oncol · 2022-01-04

该系统综述与荟萃分析检索了MEDLINE和EMBASE截至2021年10月31日的文献,纳入21篇发表于1980年至2021年的文章,涵盖超过10,000例肺癌患者。在诊断时或诊断前后戒烟与总生存期改善显著相关(SRR 0.71,95% CI 0.64-0.80),在非小细胞肺癌、小细胞肺癌及混合或未指定组织学类型肺癌中结果一致。结论认为在诊断时或诊断前后戒烟对肺癌患者生存有益,医生应教育患者戒烟并提供戒烟支持。

要点

  • 在诊断时或诊断前后戒烟与肺癌患者总生存期改善显著相关(SRR 0.71,95% CI 0.64-0.80)。
  • 非小细胞肺癌(SRR 0.77,95% CI 0.66-0.90,8项研究)和小细胞肺癌(SRR 0.75,95% CI 0.57-0.99,4项研究)中均观察到一致关联。
  • 医生应教育肺癌患者即使确诊后戒烟也有益处,并提供必要的戒烟支持。

核心结论

  • 在诊断时或诊断前后戒烟与肺癌患者生存期改善相关。
  • 治疗医生应教育肺癌患者即使确诊后戒烟也有益处,并提供必要的戒烟支持。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和EMBASE截至2021年10月31日发表的文献。
  • 纳入21篇发表于1980年至2021年的文章,涵盖超过10,000例肺癌患者。
  • 研究间在设计、患者特征、接受的治疗、用于定义吸烟状态(戒烟者或持续吸烟者)的标准以及随访时长方面存在相当大的变异性。
  • 研究特异性数据采用随机效应荟萃分析模型合并为汇总相对风险(SRR)及相应的95%置信区间(CI)。

主要发现

  • 在诊断时或诊断前后戒烟与总生存期改善显著相关(SRR 0.71,95% CI 0.64-0.80)。
  • 在非小细胞肺癌患者中,戒烟与总生存期改善显著相关(SRR 0.77,95% CI 0.66-0.90,研究数=8)。
  • 在小细胞肺癌患者中,戒烟与总生存期改善显著相关(SRR 0.75,95% CI 0.57-0.99,研究数=4)。
  • 在两种或未指定组织学类型肺癌患者中,戒烟与总生存期改善显著相关(SRR 0.81,95% CI 0.68-0.96,研究数=6)。

关键数值与推荐

  • 在诊断时或诊断前后戒烟与总生存期改善显著相关(SRR 0.71,95% CI 0.64-0.80)。
  • 非小细胞肺癌患者中戒烟与总生存期改善显著相关(SRR 0.77,95% CI 0.66-0.90,研究数=8)。
  • 小细胞肺癌患者中戒烟与总生存期改善显著相关(SRR 0.75,95% CI 0.57-0.99,研究数=4)。
  • 两种或未指定组织学类型肺癌患者中戒烟与总生存期改善显著相关(SRR 0.81,95% CI 0.68-0.96,研究数=6)。

临床怎么用

  • 作者建议治疗医生应教育肺癌患者即使确诊后戒烟也有益处,并提供必要的戒烟支持。

局限性

  • 研究间在设计、患者特征、接受的治疗、用于定义吸烟状态(戒烟者或持续吸烟者)的标准以及随访时长方面存在相当大的变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lung cancer (LC) remains a disease with poor prognosis despite recent advances in treatments. Here, we aimed at summarizing the current scientific evidence on whether quitting smoking at or around diagnosis has a beneficial effect on the survival of LC patients. METHODS: We searched MEDLINE and EMBASE for articles published until 31st October, 2021, that quantified the impact on LC patients' survival of quitting smoking at or around diagnosis or during treatment. Study-specific data were pooled into summary relative risk (SRR) and corresponding 95% confidence intervals (CI) using random effect meta-analysis models. RESULTS: Twenty-one articles published between 1980 and 2021 were included, which encompassed a total of over 10,000 LC patients. There was substantial variability across studies in terms of design, patients' characteristics, treatments received, criteria used to define smoking status (quitters or continued), and duration of follow-up. Quitting smoking at or around diagnosis was significantly associated with improved overall survival (SRR 0.71, 95% CI 0.64-0.80), consistently among patients with non-small cell LC (SRR 0.77, 95% CI 0.66-0.90, n studies = 8), small cell LC (SRR 0.75, 95% CI 0.57-0.99, n studies = 4), or LC of both or unspecified histological type (SRR 0.81, 95% CI 0.68-0.96, n studies = 6). CONCLUSIONS: Quitting smoking at or around diagnosis is associated with a beneficial effect on the survival of LC patients. Treating physicians should educate LC patients about the benefits of quitting smoking even after diagnosis and provide them with the necessary smoking cessation support.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Caini S, Del Riccio M, Vettori V, et al. Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2022. PMID: 34995798. doi:10.1016/j.jtho.2021.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。